Neuphoria Therapeutics Inc Cash Flow Conversion Efficiency
Neuphoria Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) has a cash flow conversion efficiency ratio of 0.048x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.19 Million) by net assets ($24.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neuphoria Therapeutics Inc (1999–2026)
Cash flow conversion efficiency of Neuphoria Therapeutics Inc from 1999 to 2026. This chart illustrates how Neuphoria Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NEUP stock price for real-time trading data and today's change.
Neuphoria Therapeutics Inc Cash Flow Conversion Ratio Explained
Neuphoria Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neuphoria Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuphoria Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Neuphoria Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Locksley Resources Ltd
AU:LKY
|
-0.227x |
|
SyntekaBio Inc
KQ:226330
|
-0.098x |
|
Alpha Microelectronics
TWO:8024
|
-0.018x |
|
Pensonic Holdings Bhd
KLSE:9997
|
-0.029x |
|
OURGAME INT.HOL.DL-00005
F:13O
|
N/A |
|
Baid Finserv Limited
NSE:BAIDFIN
|
0.008x |
|
New Bubbleroom Sweden AB
ST:BBROOM
|
0.097x |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
-0.276x |
Annual Cash Flow Conversion Efficiency for Neuphoria Therapeutics Inc (1999–2026)
The table below shows the annual cash flow conversion efficiency of Neuphoria Therapeutics Inc from 1999 to 2026. Review Neuphoria Therapeutics Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $24.60 Billion | $-12.35 Billion | -0.502x | -118.77% |
| 2025-06-30 | $28.87 Million | $77.23 Million | 2.675x | +418.66% |
| 2024-06-30 | $17.49 Million | $-14.68 Million | -0.839x | -24.91% |
| 2023-06-30 | $14.65 Million | $-9.85 Million | -0.672x | -75.80% |
| 2022-06-30 | $56.91 Million | $-21.75 Million | -0.382x | -141.35% |
| 2021-06-30 | $35.76 Million | $-5.66 Million | -0.158x | +48.54% |
| 2020-06-30 | $8.71 Million | $-2.68 Million | -0.308x | +65.04% |
| 2019-06-30 | $12.39 Million | $-10.91 Million | -0.880x | +27.00% |
| 2018-06-30 | $12.46 Million | $-15.02 Million | -1.206x | -2503.99% |
| 2017-06-30 | $31.09 Million | $-1.44 Million | -0.046x | +90.44% |
| 2016-06-30 | $31.69 Million | $-15.36 Million | -0.485x | -340.76% |
| 2015-06-30 | $24.52 Million | $4.94 Million | 0.201x | +165.79% |
| 2014-06-30 | $42.20 Million | $-12.91 Million | -0.306x | -10.78% |
| 2013-06-30 | $37.79 Million | $-10.44 Million | -0.276x | -148.56% |
| 2012-06-30 | $26.51 Million | $-2.95 Million | -0.111x | +56.82% |
| 2011-06-30 | $30.67 Million | $-7.89 Million | -0.257x | +19.46% |
| 2010-06-30 | $21.64 Million | $-6.92 Million | -0.320x | -11.38% |
| 2009-06-30 | $15.09 Million | $-4.33 Million | -0.287x | -6.59% |
| 2008-06-30 | $20.60 Million | $-5.54 Million | -0.269x | +11.10% |
| 2007-06-30 | $19.25 Million | $-5.83 Million | -0.303x | +35.21% |
| 2006-06-30 | $8.12 Million | $-3.80 Million | -0.467x | -15.05% |
| 2005-06-30 | $8.14 Million | $-3.31 Million | -0.406x | +15.00% |
| 2004-06-30 | $6.24 Million | $-2.98 Million | -0.478x | +13.99% |
| 2003-06-30 | $4.52 Million | $-2.51 Million | -0.556x | -7.28% |
| 2002-06-30 | $5.62 Million | $-2.91 Million | -0.518x | -3.23% |
| 2001-06-30 | $5.20 Million | $-2.61 Million | -0.502x | -79.68% |
| 2000-06-30 | $3.02 Million | $-843.87K | -0.279x | -196.31% |
| 1999-06-30 | $-363.81K | $-105.47K | 0.290x | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also deve… Read more